undamentalytics Newsletter
Sign in

Capricor Therapeutics, Inc. income statement

In fiscal 2025, Capricor Therapeutics, Inc. reported revenue of $0, down 100.0% on the year before and net income of −$105m, or −$2.26 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue10156432100325220
Research and development435814161112581422365084
General and administrative2123455546810131524
Operating income−5−2−7−6−13−17−13−15−8−14−21−30−24−43−108
Interest expense00000000—————03
Income before tax—————————————−40−105
Income tax—0———————————00
Net income−1−2−9−6−13−192−15−8−14−20−29−22−40−105
Diluted EPS−$0.33−$0.53−$2.13−$1.32−$2.02−$2.52$0.23−$0.13−$0.52−$0.88−$0.87−$1.18−$0.83−$1.15−$2.26
Diluted shares (average)15m4m4m5m6m7m11m12m15m16m23m25m27m35m46m
EBITDA−5−2−7−6−13−17−13−15−8−14−21−29−23−41−106

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CAPR vs JANXCAPR vs CRSPABEO vs CAPR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Capricor Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Capricor Therapeutics, Inc.